Altum Sequencing, S.L.
Provides best approaches for cancer cell monitoring, helping patients to know the evolution of their disease and clinicians to better decide when and how to treat them.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
N/A | Support Program | ||
| Total Funding | 000k | ||
| EUR | 2019 | 2020 | 2021 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 1255 % | (23 %) | - | 39 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (55 %) | 67 % | 45 % | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (48 %) | 51 % | 26 % | (15 %) | (36 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Altum Sequencing is a biotechnology company that has developed a proprietary method for monitoring cancer. The company specializes in liquid biopsy tests designed to guide cancer therapy and monitor for minimal residual disease (MRD). This technology allows for the detection of tumor cells that may have survived treatment.
By identifying specific genetic markers of a tumor, Altum Sequencing's services enable clinicians to personalize treatment plans. This can involve intensifying treatment if residual disease is detected or reducing it when it is safe to do so, which helps in minimizing side effects and improving patient outcomes. The company's primary clients include researchers, biopharmaceutical companies, and clinicians who are involved in oncology.
Altum Sequencing's business model is centered around providing a comprehensive portfolio of services that support patients throughout all stages of their cancer treatment. The company's main offering is a test called ClonEv®, which is used for the early detection of relapse and for monitoring the effectiveness of cancer therapies.
Keywords: liquid biopsy, cancer monitoring, minimal residual disease, oncology, biotechnology, personalized medicine, cancer diagnostics, genetic markers, cancer therapy, clinical trials